English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Background: Gastrointestinal Stromal Tumors (GIST) are mesenchymal malignancies in GI tract. GIST resistant to imatinib therapy are widely reported. Epidermal Growth Factor Receptor (EGFR) plays a role in progressivity of malignancy. This study aimed at analyzing the expression of EGFR on GIST that leads to the probability of using Anti-EGFR as a substitutive therapy for Imatinib-resistance GIST. Methods: This study performed in Dr. Soetomo General Hospital in CD-117 positive GIST from 2009 to 2014. The number of the samples were 39, samples were measured using semi quantitative method, and analyzed using Spearman formula. Results: CD-117 positive GIST showed EGFR expression in 74.4% samples, Correlation between EGFR expression with the tumor size (p=0.129) and mitotic index (p=0.626). Conclusion: CD-117 positive GIST showed EGFR expression in 74.4% samples, though there was no significant correlation between EGFR expression with tumor size (p=0.129) and mitotic index (p=0.626).

Correlation between GIST positive CD117 with EGFR expression based on tumor size and mitotic index